Insider Selling: Prestige Consumer Healthcare Inc. (NYSE:PBH) SVP Sells 1,678 Shares of Stock

Prestige Consumer Healthcare Inc. (NYSE:PBH) SVP Mary Beth Fritz sold 1,678 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the sale, the senior vice president now owns 17,157 shares in the company, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $82.83 on Thursday. Prestige Consumer Healthcare Inc. has a 52 week low of $62.35 and a 52 week high of $90.04. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $4.10 billion, a P/E ratio of 19.40, a PEG ratio of 2.69 and a beta of 0.46. The firm’s 50 day moving average is $81.22 and its two-hundred day moving average is $78.12.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on PBH shares. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. DA Davidson raised their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a research note on Friday, February 7th. Canaccord Genuity Group raised their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, February 7th. StockNews.com lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research note on Monday. Finally, Oppenheimer raised their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a research note on Thursday, February 13th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $92.60.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its holdings in Prestige Consumer Healthcare by 3.2% during the third quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock worth $19,630,000 after buying an additional 8,533 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Prestige Consumer Healthcare by 4.0% during the third quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock worth $95,678,000 after buying an additional 50,961 shares in the last quarter. Avior Wealth Management LLC boosted its holdings in Prestige Consumer Healthcare by 1,570.7% during the fourth quarter. Avior Wealth Management LLC now owns 8,554 shares of the company’s stock worth $668,000 after buying an additional 8,042 shares in the last quarter. Barclays PLC boosted its holdings in Prestige Consumer Healthcare by 346.3% during the third quarter. Barclays PLC now owns 92,444 shares of the company’s stock worth $6,665,000 after buying an additional 71,730 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in Prestige Consumer Healthcare by 171.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 46,931 shares of the company’s stock worth $3,665,000 after buying an additional 29,649 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.